Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice
Francesco Lasorsa(University of Bari Aldo Moro), Giuseppe Lucarelli(University of Bari Aldo Moro), Octavian Sabin Tătaru(Universitatea de Medicină, Farmacie, Științe și Tehnologie „George Emil Palade” din Târgu Mureș), Nicola Antonio di Meo(University of Bari Aldo Moro), Michele Battaglia(University of Bari Aldo Moro), Martina Milella(University of Bari Aldo Moro), Pasquale Ditonno(University of Bari Aldo Moro), Felice Crocetto(University of Naples Federico II), Riccardo Autorino(Cleveland Clinic), Monica Rutigliano(University of Bari Aldo Moro), Savio Domenico Pandolfo(University of L'Aquila), Matteo Ferro(European Institute of Oncology)
Cited by 161
Related Papers
Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
|International Journal of Molecular Sciences|2022|190
Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study
|Journal of Clinical Medicine|2021|131
Cellular and Molecular Players in the Tumor Microenvironment of Renal Cell Carcinoma
|Journal of Clinical Medicine|2023|129